Pfizer Inc. (ETR:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 121.60B |
| Revenue (ttm) | 54.48B |
| Net Income (ttm) | 9.18B |
| Shares Out | n/a |
| EPS (ttm) | 1.62 |
| PE Ratio | 13.25 |
| Forward PE | 8.64 |
| Dividend | 1.55 (7.27%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 69,542 |
| Average Volume | 66,091 |
| Open | 21.41 |
| Previous Close | 21.31 |
| Day's Range | 21.19 - 21.48 |
| 52-Week Range | 18.57 - 26.54 |
| Beta | 0.47 |
| RSI | 48.08 |
| Earnings Date | Nov 4, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Did Novo Nordisk Just Say "Checkmate" to Pfizer?
These two leading drugmakers are fighting over a promising GLP-1 candidate.
Pfizer (PFE) Faces Q3 Earnings Amid Market Challenges and Strategic Moves
Pfizer (PFE) Faces Q3 Earnings Amid Market Challenges and Strategic Moves
Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo
Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.
Pfizer Q3 Earnings Preview: Results to test recovery hopes amid TrumpRx deal, Metsera dispute
Check Out What Whales Are Doing With PFE
Financial giants have made a conspicuous bullish move on Pfizer. Our analysis of options history for Pfizer (NYSE: PFE) revealed 16 unusual trades. Delving into the details, we found 50% of traders w...
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market.
Pfizer Files Antitrust Lawsuit Against Metsera, Its Controlling Stockholders And Novo Nordisk
(RTTNews) - Pfizer Inc. (PFE) Monday announced on Monday that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Cour...
Pfizer (PFE) Files Second Lawsuit Against Novo Nordisk (NVO) and Metsera (MTSR)
Pfizer (PFE) Files Second Lawsuit Against Novo Nordisk (NVO) and Metsera (MTSR)
Metsera Responds to Pfizer's Legal Action Amid Bid Interest from Novo Nordisk (NVO)
Metsera Responds to Pfizer's Legal Action Amid Bid Interest from Novo Nordisk (NVO)
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership
BioNTech SE (NASDAQ: BNTX) reported a third-quarter per-share loss of 14 cents (12 cents in euros) on Monday, a turnaround from earnings of 81 cents reported a year ago, missing the consensus earning...
Biotech is back. Here's why these rallying stocks belong in your portfolio now.
The volatile sector is seeing greater stability, and these four stocks can profit.
Nasdaq Surges 1%; ON Semiconductor Posts Upbeat Q3 Earnings
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining 1% on Monday. Following the market opening Monday, the Dow traded up 0.04% to 47,583.87 while the NASDAQ rose 1.01% to 23,964....
Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera
Lawsuit says the proposed merger of the weight-loss drugmakers could kill off a smaller competitor.
Insights Ahead: Pfizer's Quarterly Earnings
Pfizer (NYSE: PFE) is preparing to release its quarterly earnings on Tuesday, 2025-11-04. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Pfizer...
Pfizer (PFE) Files Lawsuit Against Novo Nordisk Over Metsera Bid
Pfizer (PFE) Files Lawsuit Against Novo Nordisk Over Metsera Bid
Pre-Market Most Active for Nov 3, 2025 : CRBU, CURR, KVUE, CIFR, IREN, BITF, TSLL, FUBO, BMY, PFE, HKD, PCG
The NASDAQ 100 Pre-Market Indicator is up 190.14 to 26,048.27. The total Pre-Market volume is currently 273,604,382 shares traded.The following are the most active stocks for the pre-market session: C...
How To Earn $500 A Month From Pfizer Stock Ahead Of Q3 Earnings
Pfizer Inc. (NYSE: PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4 . Analysts expect the health care company to report quarterly earnings at 64 cen...
How To Earn $500 A Month From Pfizer Stock Ahead Of Q3 Earnings
Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4.
Pfizer files second lawsuit against Metsera, Novo Nordisk
Pfizer Inc said on Monday it has filed a second lawsuit against Metsera , its controlling shareholder, and Novo Nordisk in a Delaware federal court, accusing the Danish drugmaker of anticompetitive co...
Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court ...
1 Incredible Reason to Buy Pfizer Stock (PFE) in November
What would you say to a dividend yield of 7%?
Pfizer Sues Novo Nordisk Over $9 Billion Metsera Battle(edit)
Pfizer Sues Novo Nordisk Over $9 Billion Metsera Battle(edit)
Pfizer (PFE) Sues Over Metsera Acquisition Bid
Pfizer (PFE) Sues Over Metsera Acquisition Bid
Pfizer sues Metsera, Novo Nordisk to block rival bid
Pfizer sues Metsera and Novo Nordisk over a $9B acquisition bid, citing contract breaches and regulatory risks. Read more here.